INS and hyperlipidemia: Ces1g is a direct target of FXR (Xu et al., 2014a), and FXR activation is known to improve insulin sensitivity (Zhang et al., 2006), and has protective effects against hyperlipidemia (Bilz et al., 2006) and NAFLD (Carr and Reid, 2015).